Coeptis Therapeutics Expands License Agreement With Deverra To Include Pandemic Preparedness, And Emergency Use; Expansion Includes The Use Of Unmodified NK Cells In Treating Viral Infections, Pandemic-Related Illnesses, And Emergency Stockpiling For Future Health Crises
Portfolio Pulse from Benzinga Newsdesk
Coeptis Therapeutics has expanded its license agreement with Deverra Therapeutics to include the use of unmodified NK cells for pandemic preparedness and emergency use. This expansion allows Coeptis to use these cells in treating viral infections and pandemic-related illnesses, as well as for emergency stockpiling.
October 24, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Coeptis Therapeutics has expanded its license agreement with Deverra to include unmodified NK cells for pandemic preparedness and emergency use. This strategic move broadens Coeptis' application of NK cell technology, potentially enhancing its market position in treating viral infections and pandemic-related illnesses.
The expansion of the license agreement with Deverra allows Coeptis to use unmodified NK cells in new areas such as pandemic preparedness and emergency use. This could lead to new revenue streams and strengthen Coeptis' position in the biotech industry, particularly in the field of infectious diseases. The strategic alignment with current global health concerns could positively impact investor sentiment and the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100